Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Indoco Remedies's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOCO vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indoco Remedies's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indoco Remedies Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indoco Remedies's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Indoco Remedies's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indoco Remedies (NSE:INDOCO) has a Buyback Yield % of -0.06 as of Jul. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Indoco Remedies and its competitors. According to the industry distribution chart, Indoco Remedies ranks #120 out of 290 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Indoco Remedies' Buyback Yield % too high?
Indoco Remedies' current Buyback Yield % is -0.06. Based on the distribution chart, Indoco Remedies ranks #120 out of 290 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Indoco Remedies has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indoco Remedies' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Indoco Remedies ranks #120 out of 290 companies for Buyback Yield %. This puts Indoco Remedies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Indoco Remedies and its competitors. Indoco Remedies's current Buyback Yield % is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indoco Remedies stock overvalued right now?
Based on GuruFocus' analysis, Indoco Remedies (NSE:INDOCO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹367.92, compared to a current price of ₹243.42 — trading 33.8% below its estimated fair value. The current Buyback Yield % is -0.06. Indoco Remedies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Indoco Remedies (NSE:INDOCO), the current Buyback Yield % is -0.06 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indoco Remedies (NSE:INDOCO) Overvalued in 2026?
Based on GuruFocus' analysis, Indoco Remedies stock appears to be undervalued.
The current stock price of ₹243.42 is trading 33.8% below its estimated GF Value™ of ₹367.92.
GuruFocus considers Indoco Remedies to be Possible Value Trap.
Key valuation signals for NSE:INDOCO:
Buyback Yield %: -0.06
GF Value™: ₹367.92 vs. price of ₹243.42 (33.8% below fair value)
No single metric tells the full story. See the NSE:INDOCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indoco Remedies Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company manufactures products for different therapeutic sectors including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional products, Cardiology, Metabolic Disorders, and Primary Care medicines. The only operating segment of the company is Pharmaceutical Products. Geographically, it generates the majority of the revenue from India.
67GF Score
Get the complete analysis for NSE:INDOCO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOCO has been successfully added to your 
